Mechanistic Insights into the Differential Efficacy of Sonratoclax against Venetoclax-Resistant BCL2 G101V
Preprint
- 8 January 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Resistant mechanisms to venetoclax, a selective BCL-2 inhibitor approved for hematological malignancies, are frequently mediated by the G101V mutation in BCL-2. Sonrotoclax illustrates superior potency against both wild-type and G101V-mutated BCL-2, yet the mechanistic basis remains unclear. This study employed computational methods to investigate the binding dynamics of both inhibitors. Structures were predicted with AlphaFold, refined via molecular dynamics simulations (MDS), and ligands were docked with AutoDock Vina. Four systems were subjected to triplicate 200 ns MDS, with analyses including RMSD, RMSF, buried surface area, protein-ligand interaction fingerprint, and MM/GBSA binding free energies. Results indicate venetoclax exhibits progressive dissociation from G101V BCL-2, with elevated RMSD, reduced buried surface area, and increased unbound states. In contrast, Sonrotoclax maintains a steady correlation, shows persistence with entropy-enthalpy compensation, displays negligible unbound time, higher binding free energies, and constant van der Waals anchors. Having all these results in mind, a "Dynamic Blockade" hypothesis is proposed, where Sonrotoclax's flexibility enables sustained BH3 groove occupancy, blocking pro-apoptotic BH3-only proteins and overcoming allosteric perturbations induced by G101V. This mechanistic perspective proposes the optimal approach for designing resilient inhibitors to accelerate drug repurposing and development in oncology.Keywords
All Related Versions
This publication has 53 references indexed in Scilit:
- Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC PathwayAdvanced Science, 2025
- Sonrotoclax (BGB-11417) synergistically amplifies the radiotherapy-elicited anti-tumor immune responseCancer Letters, 2025
- Frustration in physiology and molecular medicineMolecular Aspects of Medicine, 2025
- Integrating machine learning and structural dynamics to explore B-cell lymphoma-2 inhibitors for chronic lymphocytic leukemia therapyMolecular Diversity, 2025
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2016
- GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputersSoftwareX, 2015
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Combating Susceptibility to Drug ResistanceLessons from HIV-1 ProteaseChemistry & Biology, 2004
- LINCS: A linear constraint solver for molecular simulationsJournal of Computational Chemistry, 1997